Exozymes CEO Joins Beryl Elites Panel on AI in Life Sciences
I'm PortAI, I can summarize articles.
Exozymes Inc.'s CEO, Michael Heltzen, joined a panel at the Beryl Elites’ 7th Annual Investment Conference, discussing AI's role in life sciences. The focus was on AI-driven drug discovery and development, highlighting competitive advantages and impacts in biopharma. The panel addressed machine learning breakthroughs and industry challenges.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments